It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The Pleiotropic Drug Resistance (PDR) network is central to the drug response in fungi, and its overactivation is associated with drug resistance. However, gene regulation of the PDR network is not well understood. Here, we show that the histone chaperone Rtt106 and the chromatin remodeller SWI/SNF control expression of the PDR network genes and confer drug resistance. In Saccharomyces cerevisiae, Rtt106 specifically localises to PDR network gene promoters dependent on transcription factor Pdr3, but not Pdr1, and is essential for Pdr3-mediated basal expression of the PDR network genes, while SWI/SNF is essential for both basal and drug-induced expression. Also in the pathogenic fungus Candida glabrata, Rtt106 and SWI/SNF regulate drug-induced PDR gene expression. Consistently, loss of Rtt106 or SWI/SNF sensitises drug-resistant S. cerevisiae mutants and C. glabrata to antifungal drugs. Since they cooperatively drive PDR network gene expression, Rtt106 and SWI/SNF represent potential therapeutic targets to combat antifungal resistance.
The Pleiotropic Drug Resistance (PDR) network is central to drug response in fungi, and its overactivation is associated with drug resistance. Here the authors show that the chromatin remodeller SWI/SNF and the histone chaperone Rtt106 are important for PDR gene expression in fungi and therefore mediate resistance to antifungal drugs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Aberdeen, Foresterhill, Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291)
2 University of Aberdeen, Foresterhill, Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291); University of Exeter, MRC Centre for Medical Mycology, Geoffrey Pope Building, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024)